Recruitment

Recruitment Status
Completed
Estimated Enrollment
80

Inclusion Criteria

Patients ≥ 18 years of age.
BRAF and/or MEK inhibitors
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
...
Patients ≥ 18 years of age.
BRAF and/or MEK inhibitors
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patient must be able to give own signed informed consent.
2nd line treatment for metastatic disease
Patients with prior adjuvant treatment are allowed.
1st line treatment for metastatic disease
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Adjuvant treatment

Summary

Conditions
  • Advanced Melanoma
  • Metastatic Melanoma
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

Patients ≥ 18 years of age.
BRAF and/or MEK inhibitors
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
...
Patients ≥ 18 years of age.
BRAF and/or MEK inhibitors
Chemotherapy regimens containing DTIC, TMZ and/or cisplatin
Patient must be able to give own signed informed consent.
2nd line treatment for metastatic disease
Patients with prior adjuvant treatment are allowed.
1st line treatment for metastatic disease
Patients were FFPE and fresh frozen tissue is available (both mandatory).
Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin.
Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies)
Adjuvant treatment

Tracking Information

NCT #
NCT02177110
Collaborators
Not Provided
Investigators
Not Provided